- |||||||||| pizuglanstat (TAS-205) / Otsuka
Journal: Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D synthase. (Pubmed Central) - Dec 24, 2022 All compounds showed high H-PGDS degrading activities, but PROTAC(H-PGDS)-4-TAS-205 (PROTAC3) was slightly less active than the other compounds. Molecular dynamics simulations suggested that the decrease in activity of PROTAC3 may be due to the lower stability of the CRBN-PROTAC-H-PGDS ternary complex.
- |||||||||| Journal: Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy. (Pubmed Central) - Nov 5, 2022
Corticosteroids such as prednisone and deflazacort are routinely given to patients to treat inflammation, but their use is limited by the occurrence of side effects and a lack of standardized prescribing...Excessive cost is a barrier to patients receiving medications that have yet to have established efficacy. Additional therapies have the potential to help patients with DMD, although most are several years away from approval for patient use.
- |||||||||| pizuglanstat (TAS-205) / Otsuka
Trial completion: Mass Balance Study of [14C] TAS-205 in Healthy Volunteers (clinicaltrials.gov) - Aug 8, 2022 P1, N=6, Completed, Additional therapies have the potential to help patients with DMD, although most are several years away from approval for patient use. Active, not recruiting --> Completed
- |||||||||| pizuglanstat (TAS-205) / Otsuka
Trial primary completion date: Mass Balance Study of [14C] TAS-205 in Healthy Volunteers (clinicaltrials.gov) - Feb 2, 2022 P1, N=6, Active, not recruiting, This study provides a current summary of prognostic indicators of disease progression in DMD, which will help inform the design of comparative analyses and future data collection initiatives in this patient population. Trial primary completion date: Apr 2022 --> Jun 2021
- |||||||||| pizuglanstat (TAS-205) / Otsuka
Enrollment closed: Mass Balance Study of [14C] TAS-205 in Healthy Volunteers (clinicaltrials.gov) - Aug 19, 2021 P1, N=6, Active, not recruiting, Further research is required to examine the effectiveness of TAS-205 in a larger trial. Not yet recruiting --> Active, not recruiting
- |||||||||| pizuglanstat (TAS-205) / Otsuka
Trial completion, Trial completion date, Trial primary completion date: A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) - Feb 6, 2018 P2a, N=33, Completed, These results suggest that combined treatment with an HPGDS inhibitor and different types of anti-allergic medicine may be a promising strategy to control nasal obstruction in AR patients. Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017 | Trial primary completion date: May 2017 --> May 2017
- |||||||||| pizuglanstat (TAS-205) / Otsuka
Enrollment closed: A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) - Dec 28, 2016 P2a, N=33, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017 | Trial primary completion date: May 2017 --> May 2017 Recruiting --> Active, not recruiting
- |||||||||| pizuglanstat (TAS-205) / Otsuka
Enrollment closed: A Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) - Jul 8, 2015 P1, N=21, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
|